Congress Materials – American College of Gastroenterology (ACG 2026)
2026 American College of Gastroenterology | Oct 9-14 | Nashville, TN
Changes in Intestinal Stenosis Among Patients With Moderately to Severely Active Crohn’s Disease Treated With Guselkumab: Results From the Phase 3 GALAXI and GRAVITI Studies
Walter Reinisch, Anita Afzali, Hamid Bassiri, Rian Van Rampelbergh, Wilhelmus van Duijnhoven, Shashi Adsul, Dylan Richards, Nat Terry, David Rubin
Deep Remission in Guselkumab-Treated Participants With Moderately to Severely Active Crohn’s Disease Through 3 Years: Results From the GALAXI 2 and 3 Studies
David T. Rubin, Anita Afzali, Christopher Busse, Rian Van Rampelbergh, Wilhelmus Van Duijnhoven, Marla Dubinsky, Geert D’Haens
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization in Patients With Inflammatory Bowel Disease Who Initiated Treatment With Guselkumab
Hsien-Yen Chang, Sumesh Kachroo
Efficacy and Safety of Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 144 From the Phase 3 GALAXI 2 & 3 Studies
Bruce E. Sands, Walter Reinisch, Geert D’Haens, Remo Panaccione, Anita Afzali, David Rubin, Jacqueline Yee, Wilhelmus van Duijnhoven, Christopher Corbett, Rian van Rampelbergh, Tadakazu Hisamatsu, Silvio Danese
Efficacy and Safety of the First Co-Antibody Therapy, JNJ-78934804, in Patients With Moderately to Severely Active Crohn’s Disease Refractory to 2 or More Systemic Therapy Mechanisms
Vipul Jairath, Geert D'Haens, Iris Dotan, Nat Terry, Monica Walker, Vanessa Bundy, Hayley Perry, Dylan Richards, Marion Vetter, Taku Kobayashi, Stefan Schreiber, Bruce E. Sands
Efficacy of Guselkumab in Perianal Fistulizing Crohn's Disease: Week 24 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter FUZION Study
Bruce E. Sands, Alisa Hart, Vipul Jairath, Tadakazu Hisamatsu, Axel Dignass, Antonio Spinelli, Susan Connor, André D’Hoore, Walter Reinisch, Silvio Danese, David Schwartz, Julian Panés, Bram Verstockt, Anton Stift, Maciej Nazar, Jacqueline Van Denderen, Talia Gramiccia, Takehiko Sakamoto, Koji Masuda, Shusheng Xu, Ivana Bravatà, Geert D’Haens, Laurent Peyrin-Biroulet
Endoscopic Outcomes of Ulcer Size and Ulcerated Surface Over One Year Across Bowel Segments in Participants With Crohn’s Disease Treated With Guselkumab: Pooled GALAXI 2 and GALAXI 3, Phase 3 Trials Analysis
Alessandro Armuzzi, Mathurin Fumery, Bruce E. Sands, Marc Ferrante, Tim Raine, Rian Van Rampelbergh, Maciej Nazar, Victoria McCaffrey, Jacqueline Van Denderen, Raja Atreya
Healthcare Professionals’ Perceptions of Intravenous and Subcutaneous Treatment Administration For Inflammatory Bowel Disease: A Real-World Study in the United States
Sumesh Kachroo, Pahul Lehal, William Jones, Fatima Dawod
Histologic and Endoscopic Efficacy of Icotrokinra, a First-in-Class Targeted Oral Peptide That Precisely Blocks the IL-23 Receptor, in Ulcerative Colitis: Outcomes From the ANTHEM-UC Study
Karen Chachu, Jimmy Limdi, Edward V. Loftus, Jr., Vipul Jairath, Maria Abreu, Minhu Chen, Edouard Louis, Katsuyoshi Matsuoka, Lindsey Surace, Ngozi Erondu, Martha Zeeman, Jia Zhan, Mary Ellen Frustaci, Grazyna Rydzewska, Britta Siegmund
Histology Outcomes Over Time in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Guselkumab in the QUASAR Long-Term Extension Study
David Rubin, Jessica Allegretti, Yelina Alvarez, Thomas Baker, Shashi Adsul, Darren Piscitelli, Ye Miao, Laurent Peyrin-Biroulet
Long-Term Efficacy and Safety of Icotrokinra, A First-in-Class Targeted Oral Peptide That Precisely Blocks the IL-23 Receptor, in Ulcerative Colitis: Results From the ANTHEM-UC Long Term Extension
Maria T. Abreu, Britta Siegmund, Lindsey Surace, Ngozi Erondu, Minhu Chen, Karen Chachu, Edouard Louis, Katsuyoshi Matsuoka, Jimmy Limdi, Nicole Houck, Mary Ellen Frustaci, Jia Zhan, Grazyna Rydzewska, Vipul Jairath, Edward V. Loftus, Jr.
Pharmacokinetics and Exposure-Response Relationships of Subcutaneous Guselkumab Maintenance in Participants With Moderately to Severely Active Crohn’s Disease
Bruce E. Sands, Geert D’Haens, Omoniyi Adedokun, Tae Eun Yang, David Rubin, Nat Terry, Rian Van Rampelbergh, Marion Vetter, Tadakazu Hisamatsu, Remo Panaccione, Silvio Danese
Pharmacokinetics and Exposure-Response Relationships of Subcutaneous Guselkumab Maintenance in Participants With Moderately to Severely Active Ulcerative Colitis
David T. Rubin, Laurent Peyrin-Biroulet, Jie Shao, Yu Kyoung Cho, Jafar Sadik Shaik, Millie Long, Silvio Danese, Yelina Alvarez, Marion Vetter, Thomas Baker, Jessica Allegretti, Tadakazu Hisamatsu
Symptomatic and Biomarker Outcomes Among Participants Treated with Guselkumab Not in Clinical Response at Week 12: Results From the Phase 3 QUASAR Induction Study
Jessica Allegretti, Alessandro Armuzzi, Jordan Axelrad, Yelina Alvarez, Thomas Baker, Caroline Kerner, Shashi Adsul, Ye Miao, Hongyan Zhang, Axel Dignass
The Efficacy and Safety of Guselkumab in Patients With Moderate to Severe Ulcerative Colitis Through Two Years: ASTRO Week 96 Results
Millie D. Long, Laurent Peyrin-Biroulet, Tadakazu Hisamatsu, Jessica Allegretti, Yelina Alvarez, Thomas Baker, Karen Hertzog, Chenglong Han, Hongyan Zhang, Ye Miao, David Rubin, Silvio Danese
Time to First Indication of Disease Progression in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Guselkumab Phase 3 QUASAR Maintenance
Jessica Allegretti, Brian Bressler, Tadakazu Hisamatsu, Bruce E. Sands, Yelina Alvarez, Thomas Baker, Shashi Adsul, Ye Miao, Hongyan Zhang, David Rubin, Axel Dignass
Treatment Gaps, Surgical Burden, and Healthcare Resource Utilization Around the Time of Diagnosis in Fistulizing Crohn's Disease: A US Claims Analysis
Hsien-Yen Chang, Sumesh Kachroo, Jennifer Seminerio-Diehl
Unsupervised Machine Learning to Identify Distinct Patient-Level Response Patterns to Guselkumab in Ulcerative Colitis: Post Hoc Analysis From the ASTRO Trial
Stefan Schreiber, Silvio Danese, Sudheer Rani, Thomas Baker, Yelina Alvarez, Long-Long Gao, Zijiang Yang, Tim Hoops, Millie D. Long
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.